Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized…

Overview of attention for article published in Breast Cancer Research, June 2016

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (80th percentile)
Good Attention Score compared to outputs of the same age and source (73rd percentile)

Mentioned by

policy: 2 policy sources

twitter: 5 X users

Citations

dimensions_citation: 150 Dimensions

Readers on

mendeley: 231 Mendeley

Summary Policy documents X Dimensions citations

So far, Altmetric has seen 2 policy documents that reference this research output.

Ibrance for Advanced Breast Cancer Resubmission – Details

Cited by Canadian Agency for Drugs and Technologies in Health on 01 Jun 2023

CADTH is an independent, not-for-profit organization responsible for providing health care decision-makers with objective evidence to help make informed decisions about the optimal use of health technologies.

Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer : Appraisal consultation committee papers

Cited by National Institute for Health and Care Excellence on 15 Oct 2018

The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.

This page shows the most recent policy documents that mention this research output.

Click here to find out how to access more activity.